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1Chapter 1
An introduction to artificial proteins
1 An introduction to artificial proteins
1.1 From native to designed proteins
Over the past several decades scientists have been trying to understand, mimic, and enhance
the tools provided by mother nature. Although considerable progress has been made to further
their understanding, the complexity and sophistication of numerous biological structures
remains bewildering. One such enigma is nature’s catalyst: the enzyme. A great deal has been
discovered about their primary, secondary, and tertiary structures, and many of the working
mechanisms have been uncovered together with their substrate ranges and limitations.1 In
addition, genetic methods have been developed to alter the amino acid sequences in enzymes
and thereby modify their performance.2 However, one aspect still remains a mystery: how the
primary structure determines the folded conformation of the protein, and thereby influences and
governs the function and performance of the enzyme. Although a great deal of work has already
been undertaken to unravel this puzzling and intriguing part of biochemistry,3 there is no doubt
that future research shall lead to far deeper insights.
De novo design involves devising a peptide sequence that will give rise to a predicted
protein structure.4–6 This requires a comprehensive understanding of the processes involved in
the translation of the amino acid sequence to the tertiary structure of a protein. Many of the
reports that have appeared so far in the literature have dealt with the design and synthesis of de
novo proteins merely as an academic exercise. With an enhanced understanding of the
complicated protein folding mechanisms, the design and synthesis of an increasing number of
functional artificial proteins has been made possible.7 These designed structures are in general
relatively small, and are more accessible to the study and understanding of complex interactions
that are involved in larger native enzymes. Designing large globular or native-like proteins is still
a challenge waiting to be accomplished. The development of new artificial proteins will no
doubt be boosted by the application of new technology, like combinatorial approaches and
high-through-put screening. An effective rationale for the design, however, is still essential to the
successful outcome of the overall protein structure.
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1.2 From mimic to artificial enzyme
Function can be introduced into a protein scaffold by the incorporation of a new reactive centre.
Conversely, a lot of research has been devoted to the design of small molecule catalysts8 or
supramolecular assemblies9 that can mimic the function of a natural enzyme. In our group we
have developed a pentadentate ligand as a model for the glycopeptide bleomycin.10 This ligand
is called N4Py (1) and consists of four pyridine rings that are anchored to a central nitrogen
atom (Figure 1.1).11 When its iron(II) complex, [(N4Py)Fe(MeCN)](ClO4)2 (2), reacts with
hydrogen peroxide, a transient low-spin iron(III) hydroperoxide species is formed, which is
capable of oxidising a wide variety of organic compounds.12 In addition, it can also function as
an effective biomimetic DNA cleaving agent analogous to iron bleomycin.13 The synthesis and












Figure 1.1. N4Py (1) and its iron(II) complex [(N4Py)Fe(MeCN)](ClO4)2 (2).
A popular scaffold for the introduction of function into a peptide structure is the four-helix
bundle motif, which has been used by many researchers in the field of protein design. The
design and construction of these four-helix bundles will be briefly discussed in the following
sections, as well as some examples of newly created functional protein mimics based on this
architecture.
The work presented in this thesis describes the preliminary studies as part of a larger project,
aimed at the design and synthesis of a functional mimic of a water-soluble peroxidase. The
design strategy is to embed the N4PyFe catalyst 2 inside a four-helix bundle, where it could
function as a synthetic cofactor in the protein environment.
As can be seen in Figure 1.2, the core of the four-helix bundle is well suited to host a small
catalyst like the N4PyFe complex. However, the packing of the amino acid side chains can be
disrupted by the catalyst and thereby destabilise the four-helix bundle. In the (re)design of the
peptide bundle this potential instability can be suppressed by creating a cavity to host the
N4PyFe catalyst. At the same time, this cavity can be designed to function as an active site
within a synthetic enzyme. With an appropriate selection of proximal amino acids, a local pH
can be established to influence the oxidative behaviour of the catalytic centre. The actual
binding of the catalyst will not be perturbed by altering the peptide sequences, as these are
covalently linked to the ligand. However, the sequence will affect the overall stability of the
peptide-N4PyFe structure, and might influence the binding of the substrate and the formation of
the reactive intermediate. A successful N4Py ligand modification that enabled the attachment of
two peptide chains to the N4PyFe catalyst will be presented in more detail in Chapter 2.
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Figure 1.2. The crystal structure of N4PyFe (2) superimposed onto the backbone of
α2,14 a dimeric four-helix bundle (left: top view, right: side view). The amino acid side
chains have been omitted for clarity.15
The aim of this chapter is neither to present a complete overview of the literature with regard to
four-helix bundles and functional peptide structures, nor to provide a full understanding of the
underlying fundamental aspects. The examples discussed here have been chosen in the hope
that they will provide some understanding of the elegant structures that protein designers have
been able to create and the principles involved.
1.3 Four-helix bundles
Four-helix bundles (right) are commonly encountered motifs in
native enzymes like ferritin, tobacco mosaic virus, myohaemerythrin,
haemerythrin, cytochrome c’, cytochrome b562,16 as well as in
methane mono-oxygenase.17 These bundles consist of α-helices that
are typically fifteen to twenty-six amino acids (residues)18 long and
display a crossing angle of about 20° with a left-handed twist.19 This
is due to the side chain intercalation of adjacent helix’ surfaces.20,21
Depending on the packing restrictions of these side chains, the
diameter of the core is about 1 Å and the distance between the axes
of the helices in four-helix bundles is generally 10 ± 3  Å.22
Although the 3D arrangement of the α-helices in a four-helix
bundle motif might be considered aesthetically pleasing, it has not been the main focus of de
novo protein design because of its architecture. Its relatively simple construction and
organisation enables modular (re)design and simulation studies of the factors that determine its
shape and stability. A great deal of knowledge has been gathered over the years about four-
helix bundles that provides to some extent an understanding of the factors that govern protein
folding and stability.5e,23 Protein designers can now manipulate peptide sequences to introduce
function (Section 1.5),4 and increase the stability of the peptide structure.6c
There are many factors that can affect the stability of the α-helix, and consequently the four-
helix bundle. Over the past few years it has been suggested that a prerequisite for the formation
of an α-helix involved the incorporation of residues with a preference for α-helix formation
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(helix propensity).24 However, Hecht and co-workers demonstrated that a periodic repeat of
polar and non-polar residues in the peptide sequence can be sufficient to form an α-helix.25 The
resulting α-helices are amphiphilic, i.e. they have a hydrophilic and a hydrophobic surface
(Figure 1.3). In designed four-helix bundles, the carboxyl-termini (C-termini) are commonly
amidated and the amino-termini (N-termini) acylated to prevent these termini from becoming
charged, as this would lead to unfavourable interactions with the helix macrodipole.1,26 This
macrodipole is the result of the intramolecular hydrogen bonding that orientates all the carbonyl
groups of the peptide amide bonds in the same direction (Figure 1.3). The charge build-up is
also pH-dependent due to the different pKa-values of acidic and basic side chains that might be
present in the peptide sequence.
Figure 1.3. The hydrophilic and hydrophobic surface of an amphiphilic α-helix (left)23c
and the helix macrodipole (right).27 The letters a–g denote the positions of the
residues in a heptad.
A prerequisite for α-helices to self-assemble into a four-helix bundle in an aqueous solution is
that they are amphiphilic. Due to the hydrophobic effect,28 the hydrophobic side chains will be
buried inside the bundle to form a hydrophobic core, whereas the hydrophilic side chains will
be exposed to the aqueous medium.29 The opposite is applicable to membrane proteins and ion
channels that span the cell membrane, as the non-polar residues are then exposed to the
lipophilic nature of the membrane (Section 1.5.3).
Depending on the design, these four-helix bundles can be tetrameric (A), dimeric (B), or
monomeric (C), consisting of four single α-helices, two helix-loop-helix units, or a single peptide
chain, respectively, in which the individual helices are connected by loops (Figure 1.4).
Furthermore, four-helix bundles are classified as parallel or anti-parallel bundles, depending on
the relative orientation of the macrodipoles of the individual helices. In nature four-helix
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A B C
Figure 1.4. Tetrameric, dimeric, and monomeric four-helix bundles.30
Helical bundles are commonly presented as a helical wheel diagram, which illustrates the side
chain interactions within a cross-section of the bundle (Figure 1.5). The positions of the residues
over two helix turns are referred to by the letters a through to g, a so-called heptad. The
hydrophobic core consists of the residues at positions a and d of the heptad, whereas the
residues at positions b, c and f of the peptide sequence form the hydrophilic exterior. The
stability of four-helix bundles can be increased by the formation of interhelical salt bridges
between oppositely charged residues,31 and by optional disulphide bridges between the
helices.32,33 In addition, linking the peptides to a template or directing the assembly by
co-ordination to a metal centre will also have a favourable effect on the stability of the protein
(Section 1.4).
Figure 1.5. Helical wheel diagrams of a parallel (a) and an anti-parallel four-helix bundle
(b), viewed from the N- or the C-terminus (here Leu and Ala are represented at
positions a and d, respectively).18,23c
Although a considerable tolerance is accepted for the exact identity and precise packing of the
side chains in the secondary structure, these factors are imperative to obtain a well-defined
tertiary structure.5b,34 A general rule applied to protein design in order for the self-assembly of
helices to be selective, is that the side chain interactions between individual helices must favour
the desired assembly and destabilise competing conformations (i.e. negative design).6c For good
complementary packing in the hydrophobic core of an anti-parallel four-helix bundle,
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alternating small and large residues at positions a and d are often required (Figure 1.5b).35 Thus,
the association into a parallel four-helix bundle would result in the small side chains occupying
the same layer in the hydrophobic core, creating a cavity that is surrounded by layers of the
larger side chains (Figure 1.5a). Also, favourable electrostatic interactions between positions c
and g, and b and e of adjacent helices in anti-parallel bundles will be absent in a parallel
orientation, and consequently disfavour the formation of a parallel four-helix bundle.
Although these rules are relatively simple to incorporate into the design, the interactions
between positions a and d one helix turn up and down the bundle also need to be taken into
account. To add to the complexity of the design, the amino acid side chains can adopt several
spatial orientations. Therefore, tight packing of the hydrophobic core is the most difficult goal to
accomplish with regard to the design of native-like de novo four-helix bundles. However, this is
equally valid for the de novo design of proteins in general. Failure to achieve a tight packing
most often results in the formation of a molten globule state; a protein folding state with a high
degree of secondary structure that lacks well-defined tertiary interactions.6c,36
A rational and incremental approach to the de novo design of four-helix bundles was pioneered
by DeGrado and co-workers.5e,37 This rational design tested their understanding of the factors
involved in the folding processes of the primary structure of a protein into its 3D organisation. In
1987 this research group designed the first α-helices that self-assembled in solution to form α1, a
tetramer of α-helical structures.14 The degree of α-helicity, however, was found to be
concentration dependent, which is often the case for tetrameric assemblies. When the sequence
was shortened by four residues, crystals of α1 could be obtained that consisted of a mixture of
tetramers and hexamers.37b By connecting two units of α1 via a short loop these helix-loop-helix
units dimerised to form an anti-parallel four-helix bundle, called α2, to neutralise the overall
macrodipole effect.14 These peptide chains were extended even further by connecting four
copies of α1 via short loops. The resulting 74-residue, single chain peptide folded into a
monomeric four-helix bundle, called α4.37a Its construction was the first example of a designed
single chain polypeptide that was able to adopt a globular compact structure, which displayed
properties that lay in between a native and a molten globule protein.
The design of α4 resulted in a stability that was not only higher than that of the dimer α2
and the tetramer α1, it was also found to be more stable than most natural proteins
(∆G = 9 4 . 1  kJ/mol, versus 10–40 kJ/mol for natural proteins, Table 1.1, p. 11).37a This
stability is considered to originate from the burial and close packing of the hydrophobic leucine
residues inside the core of the bundle, thus preventing their contact with water. Other helix and
four-helix bundle stabilising factors have also been included into the design.37a
Metal-ligand interactions have also been incorporated into the design of helical bundles to
furnish more native-like structures. Handel and DeGrado introduced tetrahedral zinc(II) binding
sites into the hydrophobic core of four-helix bundles that were based on the sequence of α24,38a
and α4.38b The metal binding site consisted of histidines at three corners of a tetrahedron (H3–α4),
with the fourth position vacant for catalytic activity. The binding of zinc(II) ions did not affect the
secondary structure, but it made the overall structure more ordered, causing a change from a
molten globule state to a more native-like protein (Table 1.1, p. 11). Introduction of a second
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metal binding site (H6–α4) enhanced the stability of the protein even further, although it still
failed to adopt a native-like conformation. Similarly, Regan and Clarke also modified the
sequence of α4 to provide a tetrahedral zinc(II) binding site consisting of histidine and cysteine
residues, a chelating environment that is found in several natural metalloproteins.39
In contrast to the hierarchical development of four-helix bundles by DeGrado et al.,
combinatorial libraries have been used by Hecht and co-workers by applying what they call a
‘binary code’ strategy.25,40 This code only specifies the locations of polar and non-polar residues
in the sequence, and not the exact identity of the amino acids. For this purpose they constructed
a family of synthetic genes encoding the intrinsic genetic information that would introduce the
(non-)polar residues into the correct sequence positions (binary patterning). They subsequently
screened the created library for peptide chains that folded into monomeric four-helix bundles.
Without the implementation of a rational design, they obtained a 75-residue protein, called M–60,
that displayed native-like behaviour.41
Other synthetic tetrameric four-helix bundles have been prepared by redesigning natural
proteins, like Rop5d,34b–d,42 or the GCN4 leucine zipper,43 or by the self-assembly of individual
α-helices.44 There are multiple examples of helix-loop-helix polypeptides that dimerise
spontaneously into anti-parallel four-helix bundles, such as GTD–43,45 SA–42,46 or the
bimetallic dimer DF1.47 Single chain, anti-parallel four-helix bundles have been constructed
using as many as nineteen of the twenty natural amino acids by Hecht et al. in the design of
Felix, a 79-residue polypeptide.48 In contrast, Stroud and co-workers used as few as seven
different amino acids in preparation of a 108-residue four-helix bundle.49 Chymohelizyme is an
example of a single chain, parallel four-helix bundle that was designed and synthesised in 1990
by Hahn et al. as a mimic for the serine protease chymotrypsin.50 The four peptide chains were
connected through the carboxylic ends by amide bonds via the amino side chain group of lysine
or ornithine.18 Construction of a four-helix bundle by connecting four α-helices via thioether
bonds has been demonstrated by Futaki et al.51
1.4 Template-assembled synthetic proteins
The self-assembly process of individual helices via intermolecular association is concentration
dependent. In contrast, a single chain protein will fold through intramolecular interactions to
yield a concentration independent folding that is also more stable. In natural proteins, loops and
turns are used to link sequences with secondary structure. Therefore, in 1988 Mutter and
co-workers introduced the concept of using artificial templates for the attachment of peptides in
order to bypass the protein folding problem.52 Since then extensive work has been published by
Mutter and Tuchscherer on the concept of Template-Assembled Synthetic Proteins (TASP).53
As mentioned above, the four-helix bundle is a popular motif for the study of protein
folding and the design of novel proteins. Therefore, a large number of TASPs with a four-helix
bundle topology have been described in the literature.23d,54 Some frequently applied scaffolds
will be briefly discussed in this section. Single α-helices, β-sheets, turns, and loops have also
been attached covalently to functionalised templates.53,54 The reported results illustrate that by
using a template the required minimal chain length to form α-helices in four-helix bundles can
be reduced to about nine to twelve amino acids, compared to the usually observed fifteen to
twenty-six residues (vide supra).
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Scheme 1.1. The TASP concept.55
When the peptide chains are pre-organised onto a template, the favourable free energy of
association will be sufficient to overcome the entropic cost and will direct the peptides to
associate into the desired conformation. The template in effect constrains the mobility and
orientation of the peptides, and thus can direct the assembly towards the intended peptide
structure. The size and shape of the framework is not decisive for the formation of a four-helix
bundle on a template.56 Even though the peptide bundles in principle can be randomly
orientated, it is common that these peptide chains come together to form helix bundles. After
all, these helix bundles were designed to incorporate a hydrophobic core, and thus the
hydrophobic surfaces of each helix will interact with the neighbouring helices due to the
hydrophobic effect. When the design of a TASP is directed towards the formation of an anti-
parallel four-helix bundle, the inverse orientation is facilitated mainly by the packing interactions
of the individual helices, and not by the helix macrodipoles.53h Additional linkers on the
template can help to form a helix bundle if the template itself is too small. However, the length
and structure of the linker can influence the thermodynamic stability of the TASP.56,57 For
instance, the linker might be able to form hydrogen bonds with functional groups on the
template.57
The TASP concept enables peptide chains to be brought in close proximity in order to study
the folding mechanisms of the primary sequences. Similarly to what has been suggested for
native proteins, the folding of TASPs commences through the formation of secondary structure,
followed by the construction of a compact 3D state, like three- or four-helix bundles (Scheme
1.2).53a
Scheme 1.2. The folding process of a TASP four-helix bundle.53a
Numerous molecular structures can be used as a template (Figure 1.7).58 The only requirements
for a template molecule entail stability and the ability to provide functionality (i.e. attachment
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sites) at the periphery to obtain the appropriate spatial orientation of peptides. Also, it should be
readily accessible and provide the possibility of structural modification of the template or the
peptide linkers. Obviously, the number of functional groups defines the number of peptides that
can be attached to the template. The distance between the attachment sites can be varied by the
frame of choice, and thus makes it possible to optimise the hydrophobic interactions between
the amphiphilic peptide chains. The template then serves as a (rigid) scaffold to acquire a
maximum stability for the tertiary structure. In addition, the template can contribute to the
designed protein function, for instance by providing a cavity for the substrate, or by the use of a
metalloporphyrin for oxidative or redox activity (vide infra).
Pd0H+
H2NNH2 piperidine P K A K G
Dde Fmoc
Boc
G K A K P
Alloc
Figure 1.6. Selectively removable protecting groups on a cyclic peptide template
(adopted from reference 53g).18,59
If the template consists of functional groups that can be selectively addressed, different peptide
chains can be attached in a controlled manner (Regioselectively Addressable Functionalised
Templates, RAFT).60 This can be achieved by the use of chemically different attachment sites, or
by selectively removable (orthogonal) protecting groups (Figure 1.6). Stepwise attachment of
peptide chains is also an option when equimolar amounts relative to a single functional group













































































































Figure 1.7. Template-Assembled Synthetic Proteins. (a) cyclic peptide as a template;53d
(b) cyclic peptide as a template with two additional co-ordinated haem groups;62a (c)
covalently linked tetraphenylporphyrin;63 (d) covalently linked coproporphyrin I unit;64
(e) three bipyridine tethers co-ordinated to a Ru(II) ion;65c (f) co-ordination of four
pyridine tethers to a Ru(II) ion;66 (g) a D-galacto-pyranoside as a template;67 (h) a
cavitand as a template.68
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Peptides have been covalently tethered to templates by, for instance, amide,53a,66,69–72
oxime,73,74 disulphide,75–77 and thioester78 bond formation (Scheme 1.3). Also, peptide chains
with bromo- or chloro-acetylated N-termini have been linked to thiols57,79–81 or
(thio)phenolic57,68,82 functionalities to produce a (thio)ether bond. Other methods of
chemoselective ligation are a Michael addition83 and reductive amination.61 The amino acid
sequences themselves can be readily obtained and modified through Solid-Phase Peptide
Synthesis (SPPS).84 In order to prevent unwanted side reactions, protected peptides are usually
coupled to the template. However, depending on the chosen ligation method, sometimes good
results have also been obtained using unprotected peptides that were attached to the
scaffold.62,73,78,81
The strength of the TASP approach is that by connecting individual peptides that have a
concentration dependent secondary structure, the overall structure has a significantly increased
stability that is independent of concentration.56,71 Another general observation is an increase in
α-helicity for template-bound helical bundles. Although the enhanced peptide helicity can also
be explained by intermolecular interactions of multiple TASP peptide chains, this effect has
been attributed to intramolecular interactions of a single TASP.56 By tethering peptide chains to
Table 1.1. Protein denaturation and stability parameters.a
Protein C0.5 (M) –∆GH2O (kJmol–1) Ref.
Native proteins: Lysozyme 4.2 37 85
α-Lactalbumin 3.6 18 85
Apocytochrome b562 n.d.b 13 86
Ferricytochrome b562 n.d.b 28 86
Ribonuclease 3.0 31 85
Designed four-helix bundles: (α ’–SS–α’)2 (dimer) 4.8 96.2 87a
(α– l–α–SS–α– l–α) 5.2 46.9 87b
SA–42 (dimer) ∼4 53.6 88
RA–42 (dimer) ∼1 36 88
DF1 (dimer) n.d.b 12.1 47a
Ac–α4–CONH2 6.3 64.4 38a
H6α4 3.4 10 38b
Zn2+–H6α4 5.5 43.1 38b
M–60 ∼7 ∼17 41
TASPs: Helichrome 5.2 18 64b
Metal ion-assisted 5.5 23 66
MOP1 1.3 13.7 62a
MOP1 bis-haem 2.5 30.4 62a
Carbohydrate-based 5.1 29 67c
Cavitein 8.0 95.8 57
a The data have been acquired using the equation ∆Gunf = ∆GH 2 O + mC,
89 where ∆GH 2 O is the free energy
of folding in the absence of denaturant, C is the concentration of the denaturant guanidinium hydrochloride,
and m is the co-solvation term, which is a measure of the co-operativity of the transition. C0.5 is the
concentration at which 50% of the protein is denatured. b n.d. = not determined.
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the template, stronger inter-helical interactions will be induced more than in the absence of a
template. Therefore, TASPs are generally found to be thermodynamically more stable than their
related helical peptides that are not assembled onto a template. Variations in the design of the
protein structure90 will also contribute to the differences in the reported stabilities given in Table
1.1.
1.4.1 Cyclic peptides
Templates based on cyclic peptides typically consist of ten amino acids. Four residues (usually
lysine or cysteine) are then positioned in such a way that their side chains are orientated to
provide a well-defined spatial arrangement to accommodate a four-helix bundle.53,69,71,73 As
illustrated in Figure 1.7a, the use of linkers directs the α-helices away from the template.
Therefore, the template only facilitates and directs the assembly and folding of the peptide
chains without interfering with the stabilising interactions that drive the assembly. Peptide loops
are also commonly encountered as a scaffold for TASPs.53,78,79,91 Although most of the presented
work is related to four-helix bundles on one side of the template, some additional work has also
led to the construction of TASPs with two bundles; one on either side of the template.53,91
The peptides can be grafted onto the template via their N- or C-terminus using standard
peptide coupling reactions as in the case of lysines for attachment sites. Cysteine is also
frequently used, which enables peptides to be coupled via the halide displacement of a halo-
acylated N-terminus, or by disulphide formation (Scheme 1.3). Nowadays, with the availability
of a wide range of (un)natural amino acids and a choice of numerous orthogonal protecting
groups, these peptidic templates are suited for structural variations and are readily available via
SPPS. The strength of utilising templates that contain selectively removable protecting groups is
that up to four different peptide sequences can be grafted selectively and modularly onto the
template, both in a parallel or anti-parallel orientation.
Due to the ease of a selective modular assembly of peptides onto a peptide template, these
templates have been widely used to study the relationships between the protein structure and its
stability, and the protein structure and its function.53d,e As an example, Rau and Haehnel have
designed a modular anti-parallel protein (MOP) that is based on a cyclopeptide as a template
(Figure 1.7b).62 This structure was further stabilised by the incorporation of two haem groups
sandwiched between two parallel helices, as observed in cytochrome b. These haem groups are
axially ligated by histidines in the peptide sequences.
Cyclic peptides have also been applied to TASPs that are
immobilised onto a solid phase to facilitate their synthesis and
purification.92 Recently, Haehnel and co-workers assembled a
combinatorial library of amphiphilic peptides in an anti-
parallel orientation onto a cellulose-bound template (right).93
This demonstration of the TASP concept resulted in the
construction of the first copper binding four-helix bundle by
incorporating cysteines and histidines into the peptide
sequences.93b Similarly, a library of cytochrome b mimics was
created by incorporating haem-binding sites into the design.93a
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1.4.2 Porphyrins
Construction of novel proteins with functional properties can be achieved, for instance, when a
flavin moiety94–96 or a metal binding site is incorporated.7c,97 Commonly, haem (iron
protoporphyrin IX) or porphyrins are used in the de novo design to provide an electron transfer
or redox function to the artificial haemoprotein.97b Metalloporphyrins in nature are commonly
found in haemoglobins, cytochromes, and peroxidases.98 The different types of porphyrin
structures are bound either via co-ordination to histidines residues or by covalent binding to the
protein scaffold. Natural haemoproteins can perform dioxygen transport and storage, in
addition to oxygen and hydrogen peroxide activation during catalytic oxidation reactions.
However, examples of synthetic haemoproteins mimicking these functions are less abundant in
the literature.99–101
Co-ordination of a haem or a porphyrin unit to a de novo designed haemoprotein can be
obtained by incorporating binding sites into the sequences (Figure 1.7b).62,75,97b,102,103 The four-
helix bundle motif is flexible and can diverge to accommodate a prosthetic haem group as
observed in the natural cytochromes c’ and b562.23 In general, the co-ordination of a haem or a
porphyrin structure results in an increased stability of the bundle.38b,75,102 To obtain a tightly
packed hydrophobic core, a pocket can be introduced into the design to accommodate the
haem more effectively.95,104 The stabilising effect of porphyrin structures on helical bundles does
not solely stem from the axial ligation of co-ordinating histidines. It has been shown that
hydrophobic interactions between the (hydrophobic) surfaces of the porphyrin and the
hydrophobic face of the helices also stabilise haemoproteins.105 In contrast to the
aforementioned TASPs based on peptidic templates, the metal centre of these metalloproteins
can be located anywhere within the protein bundle depending on the position of the chelating
residues. The peptides that encapsulate the metal centre can in principle influence the
accessibility of a substrate to the embedded active site, and thus might be used to induce
substrate specificity.
Choma et al. were the first to prepare a four-helix bundle in which a single haem (iron
protoporphyrin IX) was sandwiched between α-helices by bis-axial ligation of the imidazole
groups of histidine residues (Figure 1.8).104 The four-helix bundle was constructed by linking two
redesigned α2 units via a disulphide bridge. The introduction of additional histidines into the
peptide sequences can result in multi-haem proteins,62,97,102,106,107 as demonstrated by the
designed maquettes of Dutton and co-workers (see Section 1.5).32,87,108
Figure 1.8. A haem-stabilised four-helix bundle; side view (left) and top view (right).104
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Porphyrins bearing four functional groups can be used as templates for the covalent
attachment of peptides at the periphery of the macrocycle (Figure 1.7c,d).63,64,76,81,96,97b,106,109
These functionalities are commonly located in the ortho-positions of tetraphenylporphyrin (TPP)
derivatives to facilitate the close proximity of the peptide chains. Only the α,α,α,α-atropisomer
of TPP derivatives will uniformly align the attached peptides to establish the formation of the
four-helix bundle. When a flexible linker is used, the energy barrier for atropisomerisation can
be sufficiently reduced to enable free rotation.109 The hydrophobic effect will subsequently drive
the amphiphilic peptides to assemble into a four-helix bundle. Due to this design strategy, the
porphyrin template will be positioned on one side of the bundle. The appending porphyrin ring
in Helichrome thereby provides a hydrophobic pocket, which is also active in the catalytic cycle
(Figure 1.7d).64 Similarly, Åkerfeldt et al. successfully constructed a membrane ion channel
mimic, called Tetraphilin, by coupling unprotected peptides to a TPP scaffold (Figure 1.7c).63
1.4.3 Metal ion-assisted self-assembly
Metal-binding sites in proteins can be classified on the basis of either structural or functional
roles. In protein design, co-ordination of metal binding sites (ligands) in peptides to a transition
metal ion is a means of controlling the assembly process during the formation of helical bundles.
Complexation of the α-helices can occur via the covalently bound chelating groups (like
pyridine or bipyridine) at the peptide terminus,65,66,110 or via metal-binding sites inside the
hydrophobic core.47,111 The hydrophobic interactions are the driving force for the formation of
the helix bundle, whereas complexation of the ligands to the metal ion controls the number of
participating peptide chains. Lieberman and Sasaki have described the use of a 15-residue
amphiphilic α-helix with a N-terminal bipyridine tether for complexation to an iron(II) ion.110
Similarly, Ghadiri and co-workers have obtained the resulting parallel three-helix bundle by
co-ordination of bipyridine-modified 15-residue peptides around a ruthenium(II) ion (Figure
1.7e).65 This synthetic metalloprotein was used to measure electron-transfer rates, thus providing
a function for the de novo designed structure. The assembly resulted in the formation of a three-
helix bundle, due to the co-ordination of these bipyridyl moieties to the transition metals. A
stable parallel four-helix bundle was assembled by Ghadiri et al. by co-ordinating four pyridine-
modified 15-residue α-helices around a ruthenium(II) ion with two additional chloride anions as
axial ligands (Figure 1.7f).66
1.4.4 Carbohydrates
The cyclic structure of carbohydrates has also been applied as a rigid template in the
construction of TASPs. Jensen and Barany have outlined a solid-phase preparation of a
derivatised D-galactopyranose that enabled the attachment of four identical 16-residue peptides.
These peptides are linked to the four available hydroxyl functionalities of the monosaccharide
via a short spacer to yield a stable four-helix bundle (Figure 1.7g).67 The structure, however,
lacks function and has only been employed for the design study of a native-like protein.
The rigid cyclic structure of α-, β-, and γ-cyclodextrins makes it possible to assemble six,
seven, and eight peptide chains, respectively. Åkerfeldt and DeGrado have been able to prepare
a heptameric assembly by coupling 7-residue peptides to a β-cyclodextrin scaffold.112 Although
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the cyclodextrin template can potentially function as a receptor,113 practical applications for
cyclodextrins in the design of artificial enzymes have as yet not been reported by the authors.
1.4.5 Macrocycles
A number of approaches utilising macrocyclic scaffolds have been described in recent years.
These more or less rigid organic molecules contain hydrophobic cavities that offer a potential
binding site for substrate recognition, although so far no such function has been presented in the
literature. Cavitands have been applied as a template for four-helix bundles by Sherman and
co-workers (Figure 1.7f).57,68 These authors proposed the name caviteins for the de novo
designed proteins, originating from the words cavitand and proteins. By varying the length of
the spacer between the peptide and the template, they were able to study the influence of the
flexibility and rigidity of the scaffold on the overall stability of the structure. Causton and
Sherman have also designed and synthesised a three-helix bundle by attaching the peptide
chains to a rigid cyclotribenzylene (CTB) macrocycle (Figure 1.9).76 The three thiol groups on
the periphery of CTB were used to covalently link unprotected peptides with N-terminal
cysteines via disulphide bonds. Similarly, van Wageningen and Liskamp have used a
cyclotriveratrylene-based scaffold (CTV) that enabled the covalent attachment of three amino
acid sequences via amide bonds.72 The calix[4]arene has been used by Hamilton and
co-workers as a scaffold for the attachment of four peptide loops to mimic an antibody
recognition site.114
Figure 1.9. Schematic representation of CTB as a template for three-helix bundles.18,76
1.5 Artificial proteins: Function by design
Until recently, the major focus of protein design has been the understanding of the protein
folding processes and the construction of small tertiary polypeptide structures with a pre-defined
conformation. Without such an understanding of folding principles and structure-stability
relationships, the introduction of useful function into the design of artificial proteins will be
unsuccessful. It has already been mentioned that many designed protein structures behave as
molten globules. The fluctuating conformations will therefore have a negative effect on the














With regard to the designed functional proteins in this section, the focus will be directed
towards helical bundles. The active centre of the functionalised structures is usually located
inside the hydrophobic core of the four-helix bundle. Their relatively small size and ease of
modification has made four-helix bundles the most commonly studied motif for the design of
synthetic proteins. Furthermore, they have high solubilities in water and are in general relatively
stable over a wide pH-range.
Natural haemoproteins are capable of catalysing redox reactions, binding small molecules
(e.g. CO, NO, CN), and performing electron transfer reactions. These enzyme functions have all
been established by de novo designed haemoproteins.101
1.5.1 Artificial enzymes
Artificial enzymes are, almost by definition, inspired by natural enzymes.8,115 The residues used
to form the active site often resemble the substrate binding pockets of the native protein. The
substrate specificity of enzymes is determined by the arrangement of amino acid residues in the
active site that bind to the functional groups of the substrate molecules, and in the case of
metalloproteins also by the positioning of the metal ion. Therefore, in order for a designed
peptide to act truly as an enzyme mimic, these characteristics will need to be incorporated and
expressed by the artificial protein. The use of templates in the de novo design of functional four-
helix bundles not only offers the opportunity to construct more native-like proteins; the size and
shape of the template can in principle allow for selectivity during the reaction, based on the size
and nature of the substrate.
The main disadvantage of porphyrin-based (per)oxidases is their sensitivity towards
oxidative degradation, either by the oxidant or by the reactive metal-oxo intermediate.
However, it has been found that the stability of a peroxidase can be increased by the nature of
the peptide surrounding.116 The peptides are thought to act as radical scavengers or as an
alternative source for hydrogen abstraction, which would otherwise take place on the porphyrin
ring.
Substrate recognition30,117,118 and rate enhancements of more than three orders of
magnitude over background reactions117a,118,119 have been reported for reactions catalysed by
designed helical bundles (vide infra). So far, artificial proteins capable of stereospecific reduction
and oxidation have yet to be constructed, but taking into consideration the progress made over
the last few decades, even this function might become reality in the near future.
Mihara et al. have constructed an artificial flavin protein that is capable of oxidising
dihydronicotinamides.95,96 Their design consisted of a 53-residue single chain four-helix
bundle,95 or four appending α-helices on a Mn–TPP moiety96 in which all helices were identical
except for one helix with a flavin-modified cysteine in the centre of the hydrophobic core. The
oxidation of 1-benzyl-1,4-dihydronicotinamide, with a rate constant of 290 M–1s–1, was 1.35
times faster than the reaction catalysed by the unbound 7-acetylflavin moiety.95 This rate was
more than doubled (k 660 M–1s–1) when a second flavin group was introduced into the helix
bundle. By electron transfer via the flavin unit the liberated electrons in this oxidation process
were also capable of reducing the manganese(III) in the porphyrin ring to MnII–TPP.96
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By employing a combinatorial approach to the design of single chain four-helix bundles,
Hecht and colleagues have been able to obtain some haem-binding peptides that displayed
peroxidase activity.103 Although a haem-binding site had not been incorporated into the design
itself, one protein in particular, protein 86, was capable of oxidising ABTS with a maximum
turnover frequency of 17,000 min–1. Even though this is over forty times faster than any other
artificial porphyrin-based peroxidase, it is still much slower than the native horseradish
peroxidase (HRP) (∼60,000 min–1).103b Peroxidase activity has also been achieved with a
disulphide linked three-helix bundle to which a haem is covalently attached,76 and a disulphide
linked dimeric four-helix bundle that contained a co-ordinated haem group.75b The potential
oxidation of the disulphide bonds by the terminal oxidant hydrogen peroxide was not addressed
by the authors.
Mono-oxygenation of styrene and its derivatives to their epoxides has been achieved by a
peptide-modified manganese(III)TPP, using iodosylbenzene as the oxidant.80 Substrate
discrimination could be established depending on the solvent. The authors did not mention any
oxidation of the thioether linkage that had been used to span the peptide across the porphyrin.
Benson et al. have designed novel proteins that displayed superoxide dismutase (SOD)
activity of about 1% of the wild-type SOD.120
A de novo designed peptide ligase, consisting of a dimeric 33-residue amphiphilic helical
sequence, catalysed the ligation of hydrophobic peptides (Scheme 1.4) with rate enhancements























Scheme 1.4. The peptide ligation reaction.
Broo and co-workers have constructed a symmetric 42-residue helix-loop-helix homo-dimer
(KO–42) with a reactive site consisting of twelve histidine residues.30,117 This artificial enzyme is
capable of substrate specific transesterification reactions, as well as nucleophilic and general acid
hydrolysis of p-nitrophenyl esters. The pH-dependent reaction rate is up to three orders of
magnitude faster than compared to the 4-methylimidazole catalysed reaction.
Hahn et al. have reduced the sequence of the protease chymotrysin, a single chain peptide
with 245 residues, to a 73-residue protein, called Chymohelizyme.50 Although the substrate
specificity was of a similar nature and the catalyst achieved over a hundred catalytic turnovers,
the rate of hydrolysis was about one hundred times less effective than that of the natural
enzyme.
In an effort to construct a synthetic decarboxylase, Benner and co-workers have designed a
de novo enzyme, called oxaldie, that self-assembles in solution to form helical structures.119 The
rate of decarboxylation of oxaloacetate is about five orders slower than that of the natural
enzyme. However, this is still about nine hundred times faster than the uncatalysed
decarboxylation and three to four orders of magnitude faster than the reaction catalysed by
simple amines. Remarkably, oxaldie does not require any metal ions, as opposed to the natural
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oxaloacetate decarboxylases, which require magnesium or manganese ions as a cofactor. Even
less effective is the dimeric four-helix bundle NP–42, designed by Baltzer and co-workers, that
decarboxylates oxaloacetate only ten times faster than butylamine.121
The coproporphyrin-based four-helix bundle Helichrome, which was designed by Sasaki
and Kaiser to function as an aniline hydroxylase, produces p-aminophenol in the presence of
NADH and oxygen with a rate comparable to that of the natural haemoprotein haemoglobin.64
The examples presented here of functional four-helix bundles are capable of catalysing a
variety of enzymatic reactions, although most of them are often inferior to their natural
equivalents. Even though the reports in the literature only describe the successful attempts, the
fact that protein designers are now capable of designing and constructing functional synthetic
proteins, it is still seen as a quite remarkable achievement. With an increased understanding of
the processes involved, the implementation of the required adjustments into the design will no
doubt facilitate the construction of more native-like performances by artificial enzymes.
1.5.2 Redox activity
Many approaches to redox active four-helix bundles have been followed in recent years.4,7e For
the design of redox proteins the co-ordination environment for the metal can be provided by
correctly positioning two to four amino acids with chelating side chains, commonly histidine or
cysteine. These residues can be co-ordinated to a transition metal or a prosthetic group (haem
or porphyrin) with a vacant or loosely bound site for its function, such as carbon monoxide
binding.101 Metallo- and haemoproteins can display a pH-dependence for the binding of metal
ions or haem groups, as protonation of histidine will result in the dissociation of the cofactor.
With precise design, site-selective binding of different metals,122 or iron(III) and zinc(II)
protoporphyrin IX can be accomplished.108e
The work carried out by Dutton and co-workers serves as an
illustrative example of the de novo design of novel redox
proteins based on the four-helix bundle topology.32,87,108 The
initially designed assembly consisted of a parallel dimer of two
identical, disulphide-linked α-helices, each containing thirty-one
residues.32 The authors refer to these (α–SS–α)2 motifs as
‘maquettes’; simplified synthetic protein scaffolds that still retain
some of the functions of the native enzyme. Structural variations
enabled them to incorporate up to four iron haem units inside
the hydrophobic core (right)108a without significantly affecting the
helical content of the four-helix bundle.87b The nature of the
prosthetic groups was found to be able to control the parallel or
anti-parallel orientation of the protein bundle through steric
interactions.108g By connecting two helix-loop-helix (α– l–α)
units via a disulphide bridge a single chain four-helix bundle (α–
l–α–SS–α– l–α) was obtained that was somewhat more
resistant to denaturation than the dimer (Table 1.1).87b
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The use of de novo designed maquettes allowed Dutton and colleagues to selectively
introduce different haem groups,108g and construct a protein with an affinity for halothane,123 a
volatile anaesthetic guest molecule.108c In addition, they succeeded in constructing proteins with
a pH-controlled redox potential.108d Conversely, major pKa shifts were observed for the acidic
and basic groups upon reduction or oxidation of the haem group, as oxidation of the cofactor
increased its positive charge and, thereby, reduced its proton affinity. The multi-haem
maquettes display a co-operative redox behaviour, which is thought to arise from the electronic
interactions between the individual haems. As a result, they were able to acquire significant
diversity in the haem reduction midpoint potential (–350 to +175 mV at neutral pH compared
to –400 to +400 mV for natural haem proteins).108h,i A photosynthetic reaction centre was
introduced by integrating two appending coproporphyrin I moieties. However, this approach
resulted in a disappointing quantum yield of <0.01.108a
In view of the number of possible structural variations in the amino acid sequence, de novo
design of artificial (metallo)proteins lends itself to combinatorial design strategies. As an example
of a library approach, McLendon and co-workers have mutated cytochrome b562, a haem-
binding four-helix bundle peptide, at two positions in the sequence near the site for haem
binding while maintaining the original structural motif.124 The resulting structures displayed
redox potential variations of over 1000 mV.
A great deal of research has been devoted to the study of (light-induced)62b electron transfer
for de novo designed redox proteins.65,108a,124 Willner et al. have presented an elegant example
by incorporating two iron(III) protoporphyrin IX (Fe–PP) units into a four-helix bundle that was
assembled as a monolayer onto a gold electrode.106 Electron transfer was made possible by a
difference in the redox potential of the Fe–PPs due to a difference in the distance to the gold
surface. The helix bundle has also been connected covalently to a cytochrome b1-dependent
nitrate reductase, establishing a bioelectrocatalysed reduction of NO3– in 80% yield (Figure
1.10).107 Alternatively, cross-linking the helix bundle to Co–PP–reconstituted myoglobin
enabled the electrocatalysed hydrogenation of acetylene dicarboxylic acid to maleic acid

























Figure 1.10. Electrochemical reduction of cytochrome c.107b
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1.5.3 Membrane proteins and ion channels
Helical bundles have also been designed to function as ion channels that can distinguish
between small ions, like H+, Li+, K+, Na+, and Cs+. In order to act as a pore, these bundles
need to span the cell membrane. Incorporation into the lipophilic membrane requires a
hydrophobic exterior, which is contrary to the helical bundles that have been discussed so far. A
representative example by DeGrado and colleagues utilises amphiphilic helices consisting of
only leucines and serines that self-assembled into a four-helix bundle.125 The exact sequence
composition affected the packing of the protein core, which as a result directed the cation-
selectivity of the ion channel. The membrane protein in turn could be ‘coated’ by amphiphilic
helices to change the hydrophobic nature of its exterior, making the protein soluble in water.126
As observed for other TASPs, covalent attachment of the sequences to a (cyclic) peptide69,79b,127
or TPP63 template (Figure 1.7c) enhanced the stability of the synthetic pore.
1.5.4 Antibody recognition
Template-assembled synthetic proteins have also been described as functional mimics in
antibody recognition.60,114 The template is often a cyclic peptide, but also self-assembled
tetrameric and dimeric four-helix bundles have been described as an antigenic determinant.44a
By duplicating only the functional part of a protein (Figure 1.11), the properties of the large
natural enzyme can be effectively replicated. Normally, small antigen mimics are rapidly
degraded in vivo, unless the sequences are assembled as loops onto a scaffold or protein.128
Antibody TASP
Figure 1.11. Receptor mimetics using regioselectively addressable templates.53f
These small designed, synthetic peptides are capable of liberating antibodies that can for
instance recognise the natural HLA–A2 antigen.128 It is also worthwhile mentioning that self-
assembled monolayers of TASP molecules on a gold surface have been examined as potential
biosensors.53e
1.6 Research objectives and outline of this thesis
The presented examples of functional enzyme mimics based on the four-helix bundle motif
clearly demonstrate that these small peptide bundles can be provided with a function that
resembles that of a larger protein structure. Although a great deal of progress has been made in
the last decade towards the design of small peptide structures, designing architectures that have
function as well as a defined construction still remains an extremely difficult task to master and
should not be underestimated.

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Despite all the examples of functional four-helix bundles presented in the literature, so far
no examples have been published for the design of a synthetic peroxidase or oxygenase-based
on a non-haem catalytic centre. The small oxidising catalyst N4PyFe that was developed in our
group opens up an opportunity to create such a functional enzyme mimic. The design strategy is
to embed the catalyst inside a four-helix bundle by attaching four helical peptides via a cysteine
residue to a tetrafunctionalised N4Py ligand. Suffice it to say that the position of the cysteine in
the peptide sequence will enable a site-specific introduction of the catalyst into the core of the
bundle. In Scheme 1.5 a schematic representation of this concept is depicted where the four-
helix bundle is tethered to the catalyst via a terminal cysteine residue. Alternatively, if the
cysteine residues are positioned centrally in the peptide sequence, the N4PyFe catalyst will be
situated in the middle of the bundle (Figure 1.2). The relative orientation of the individual
helices is then an issue, which could be controlled by directed interactions that will favour the
designed helix bundle. First, we need to evaluate the feasibility of this ambitious project.
Scheme 1.5. Schematic representation of tethering a four-helix bundle to the N4PyFe
catalyst.
The aim of the research presented in this thesis is to develop modified N4Py ligands that will
enable the covalent attachment of four peptide chains. Once that has been accomplished
successfully, peptide sequences can be selected, which have been designed to fold into a four-
helix bundle. However, before the catalyst is incorporated into a bundle protein, it needs to be
ascertained whether or not the attached peptides can withstand the oxidising conditions, as well
as the highly reactive iron-oxo intermediate, and thereby do not diminish the catalyst activity.
We first tested this concept by attaching two peptide chains to a disubstituted N4Py ligand
(Chapter 2).15 The iron(II) complex retained its catalytic oxidation activity with hydrogen
peroxide in water. Subsequently, the N4Py ligand was successfully modified into a template by
the introduction of functional groups. This enabled the application of the TASP methodology to
the N4Py ligand and established the incorporation of the N4PyFe catalyst in a peptide
environment by the covalent attachment of four peptides (Chapter 3).
The presented synthetic route follows a convergent strategy for the construction of
tetrafunctionalised N4Py ligands. An alternative, a divergent synthesis has also been developed
that facilitated the construction of the N4Py skeleton prior to its functionalisation (Chapter 4).
The potential strength of this latter method is that it will also enable structural variations using




And finally, the application of several tetrasubstituted N4PyFe catalysts in oxidation reactions
will be discussed in Chapter 5, as well as the peroxidase activity of an assembled N4PyFe-
peptide complex. As is commonly found for oxidising haemoproteins, the N4PyFe catalyst and
the peptide-bound equivalents are also susceptible to oxidative degradation. Optimisation of the
peptide surrounding could eventually result in a prolonged lifetime of the future non-haem
peroxidase.
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